A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

  • STATUS
    Recruiting
  • End date
    Jun 23, 2027
  • participants needed
    240
  • sponsor
    Sanofi
Send
Updated on 21 July 2023
See if I qualify

Summary

This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy for participants aged at least 18 years with advanced unresectable or metastatic malignancies.
The study will include 2 parts:
A dose escalation Part 1: for finding the recommended dose(s) of SAR445877 in a monotherapy given every 2 weeks (Q2W) or weekly (QW).
A multicohort dose expansion Part 2: for the assessment of safety and preliminary efficacy of SAR445877 in monotherapy (2 dose levels will be tested in at least 1 indication as applicable).
Approximately 240 participants will be enrolled to the study intervention:
For Part 1: approximately 75 participants, For Part 2: up to 30 participants will be enrolled in each cohort per dose level for a total of approximately 165.

Description

The duration of the study for a participant will include:
Screening Period: up to 28 days Treatment Period: enrolled and exposed participants will receive continuous treatment until progressive disease (PD), or an occurrence of an unacceptable AE, a withdrawal of consent, or until other permanent discontinuation criteria described in the protocol are met.
The End of Treatment (EOT) visit will occur 30 days ±7 days from the last IMP administration or prior to the initiation of further therapy, whichever occurs first.
The follow-up period will occur until disease progression, the start of new anticancer therapy, death, or withdrawal of participant's consent, whichever comes first.

Details
Condition Solid Tumor
Age 18years or above
Treatment SAR445877
Clinical Study IdentifierNCT05584670
SponsorSanofi
Last Modified on21 July 2023

Eligibility

 Yes No Not Sure

Inclusion Criteria

Dose escalation Part 1
Participants with advanced unresectable or metastatic solid tumors for which, in the judgement of the investigator, no standard alternative therapy is available or is not in the best interest of the participant Dose expansion Part 2
Cancer diagnosis
Participants in Cohort A: Histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC)
Participants in Cohort B: Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic hepatocellular carcinoma (HCC), or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients (patients without cirrhosis must have had histological confirmation of diagnosis)
Participants in Cohort C: Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic gastric cancer (GC) or Siewert Type 2 & 3 gastro esophageal junction (GEJ) adenocarcinoma
For participants in Cohort C: Disease with CPS scoring of <1 as determined at local laboratory with an Agency approved test (for the other cohorts: Disease with any CPS scoring. No need for CPS determination at local laboratory)
For participants in Cohort C: Participants must have MSI XE 'MSI' \f Abbreviation \t 'metastatic microsatellite instability' or MMR XE 'MMR' \f Abbreviation \t 'mismatch repair' status known or determined locally and must have non-MSI-H or proficient MMR (pMMR) disease to be eligible
For participants in Cohort C: Participants with unknown HER2/neu status must have their HER2/neu status determined locally. Participants with HER2/neu negative are eligible. Participants with HER2/neu positive tumors must have documentation of disease progression on treatment containing an approved HER2 targeted therapy to be eligible
Measurable Disease
At least 1 measurable lesion per RECIST 1.1 criteria. Capable of giving signed informed
consent

Exclusion Criteria

Eastern Cooperative Oncology Group (ECOG XE 'ECOG' \f Abbreviation \t 'Eastern
Cooperative Oncology Group' ) performance status of ≥2
Predicted life expectancy ≤3 months
For participants with HCC- Cohort B (Part 2): Child Pugh Class B or C liver score
Participants with Child Pugh Class B-7 score are allowed for Part 1
Diagnosed of any other malignancies, either progressing or requiring active
treatments, within 2 years prior to enrollment
Known active brain metastases or leptomeningeal metastases
History of treatment-related immune-mediated (or immune-related) AEs from
immune-modulatory agents (including but not limited to anti-PD1/PD-L1 agents and
anti-cytotoxic T lymphocyte associated protein 4 monoclonal antibodies) that caused
permanent discontinuation of the agent, or that were Grade 4 in severity or have not
resolved to Grade ≤1
Has any condition requiring ongoing/continuous corticosteroid therapy (>10 mg
prednisone/day or an anti-inflammatory equivalent) within 1 week prior to the first
dose of the study medicine
Any clinically significant cardiac (including valvular) or vascular (thromboembolic
disorders) disease, within 6 months prior to the first IMP administration
Ongoing or recent (within 2 years) evidence of significant autoimmune disease that
required treatment with systemic immunosuppressive treatments, which may suggest risk
for immune-related adverse events
Has a known history or any evidence of interstitial lung disease or active
non-infectious pneumonitis within 3 years prior to the first dose of the study drug
Organ transplant requiring immunosuppressive treatment
Uncontrolled or active infection with human immunodeficiency virus (HIV), hepatitis B
or hepatitis C infection, or has a diagnosis of immunodeficiency
NOTE: Other Inclusion/Exclusion criteria may apply
The above information is not intended to contain all considerations relevant to a potential
participation in a clinical trial
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.